Merial Receives Approval For New Vaccine To Prevent
Schmallenberg Disease In Livestock
SBVvax prevents viremia against Schmallenberg Virus in both sheep and
France – 9 August, 2013 – Merial, the animal
health division of Sanofi, today announced the grant of a Market Authorization
under exceptional circumstances for SBVvax
in France, a new inactivated vaccine against Schmallenberg Virus (SBV)
SBV is an entirely new virus first identified at
the end of 2011. The virus has been detected in wide range of animals but
impact primarily domestic ruminants such as sheep and cattle. SBV is spreading
rapidly and extensively throughout Europe. There have been more than 8,000 farms
with confirmed cases SBV in Europe from September 2011 – April 2013.
The disease includes acute cases in adult animals associated
to milk drop, diarrhea and fever but the key consequences are congenital cases
in offspring inducing malformations. Despite a clear underreporting of cases
and a lack of supportive data for such a new disease, preliminary studies on
the impact of SBV on reproduction and productivity performance in cattle and
sheep have shown a significant economic impact due to issues including still
births, malformed newborns, low milk production and adult animal deaths. A
report from France recorded that, in highly impacted farms by SBV, 41% of lambs
were born malformed.
SBV is vector-borne and not a contagious disease.
Vector-borne diseases spread quickly and can infect any animal from the herd.
There is no known treatment for SBV disease, so vaccination is the key tool to
prevent the spread within herds whatever the vector or the transmission.
SBVvax is indicated for active immunization to prevent viremia due to the Schmallenberg virus in sheep and cattle. In
clinical efficacy studies, SBVvax
showed prevention of viremia in 100% of the infected lambs and calves. The
vaccination protocol for the inactivated injectable vaccine is one shot of 1ml
for sheep, and two shots of 1ml for cattle, 3 weeks apart. SBVvax will be available as suspension in a 50ml bottle.
For over 50 years, Merial, has partnered with veterinary health authorities throughout the world to prevent and control the spread of infectious animal diseases of major social and economic importance. “When SBV arrived, we did everything we could to offer to our
customers a high quality vaccine in a record time,” says Dr. Silke Birlenbach,
head of Veterinary Public Health. “After having
successfully developed the leading vaccine against the emergent Bluetongue
serotypes in Europe, Merial is now applying that expertise to the
newly-emerging problem of Schmallenberg Virus disease.”
“The first priority for us was to have a solution
to protect herds, now we are looking forward to partnering with veterinarians, and the livestock and research community to enhance our understanding
of this novel disease” Dr. Silke Birlenbach added.
Vvax doses will be available to veterinarians before
October in France.
The vaccine is also under review in the UK by VMD. The
official indication and availability of doses will be communicated when the
provisional license is granted.
Contact: Natasha Mahanes
+1 - 678-638-3690